Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
#What Is The Projected Market Size Of The Monoclonal Antibody Therapeutics Market By 2029?
The monoclonal antibody therapeutics market has experienced rapid growth in recent years. It is projected to expand from $199.98 billion in 2024 to $224.62 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.3%. This market’s historical expansion is attributable to the increasing prevalence of chronic diseases, rising demand for targeted therapies, growing adoption in oncology treatment, the expansion of biopharmaceutical manufacturing, government funding for biologics research, and the rising incidence of autoimmune diseases.
The monoclonal antibody therapeutics market is projected to experience substantial expansion over the coming years. Its valuation is anticipated to reach $354.11 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.1%. This anticipated growth during the forecast timeframe is primarily driven by factors such as the expansion of personalized medicine, an increase in the elderly population, a broader range of applications for approved mAbs, higher expenditure on healthcare, and enhanced understanding among medical professionals. Key trends expected during this period involve the creation of bispecific antibodies, progress in hybridoma technology, the application of AI in finding new antibodies, breakthroughs in glycoengineering, continuous bioprocessing methods, and gene editing instruments designed to improve expression.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25839&type=smp
What Are The Drivers Pushing New Developments In The Monoclonal Antibody Therapeutics Market?
The increasing incidence of autoimmune conditions is projected to stimulate the expansion of the monoclonal antibody therapeutics market in the coming period. Autoimmune diseases are characterized by the body’s immune system mistakenly attacking its own healthy tissues and organs, interpreting them as foreign threats, which leads to chronic inflammation and tissue damage. The prevalence of these diseases is rising due to environmental factors, as heightened exposure to pollutants and altered microbial environments are believed to trigger abnormal immune responses in susceptible individuals. Monoclonal antibody therapeutics are beneficial for autoimmune diseases because they precisely target and block specific immune pathways responsible for inflammation and tissue destruction, helping to alleviate symptoms and slow the progression of the illness. For instance, in March 2023, a report issued by the Office for Health Improvement & Disparities, a UK-based government department, indicated that in 2022, 17.6% of individuals aged 16 and over self-reported a long-term musculoskeletal (MSK) condition, a health issue often caused by autoimmune diseases, marking an increase from 17.0% in 2021. Thus, the growing prevalence of autoimmune diseases is fostering the growth of the monoclonal antibody therapeutics market.
Which Key Segments Fueling The Monoclonal Antibody Therapeutics Market?
The monoclonal antibody therapeutics market covered in this report is segmented –
1) By Product Type: Naked, Fusion Protein, Antibody Fragment, Conjugate, Multi-Specific
2) By Therapy Area: Autoimmune And Inflammatory Disorders, Oncology, Hematology, Ophthalmology, Other Therapy Areas
3) By Application: Cancer, Autoimmune Diseases, Infection, Hematological Diseases, Other Applications
4) By End User: Hospitals, Private Clinics, Research Institute
Subsegments:
1) By Naked: Fully Human Antibodies, Humanized Antibodies, Chimeric Antibodies
2) By Fusion Protein: Receptor Fusion Proteins, Ligand Fusion Proteins
3) By Antibody Fragment: Single-Chain Variable Fragment, Fab Fragments, Diabodies
4) By Conjugate: Antibody-Drug Conjugates, Radioimmunoconjugates, Immunotoxins
5) By Multi-Specific: Bispecific Antibodies, Trispecific Antibodies, T-Cell Engagers
How Are Trends Influencing The Monoclonal Antibody Therapeutics Market?
Companies operating within the monoclonal antibody therapeutics market are prioritizing the introduction of innovative solutions, such as bispecific monoclonal antibodies, aiming to improve treatment efficacy by simultaneously addressing two different antigens or epitopes. Bispecific monoclonal antibodies represent a specialized category of engineered antibodies capable of concurrently binding to two distinct antigens or two separate epitopes on the same antigen. For example, in March 2024, Roche Holding AG, a pharmaceutical company based in Switzerland, launched Vabysmo (faricimab-svoa). This bispecific monoclonal antibody is intended for eye conditions, specifically designed to treat neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). It targets both VEGF-A and Angiopoietin-2 (Ang-2), thereby promoting improved vascular stability and decreasing retinal fluid leakage. This dual-target mechanism enables extended dosing intervals of up to four months, substantially reducing the treatment burden for patients.
Who Are The Key Multinational Companies Dominating The Monoclonal Antibody Therapeutics Market?
Major companies operating in the monoclonal antibody therapeutics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Genmab A/S, ADC Therapeutics, Arcus Biosciences, Y-mAbs Therapeutics
Download The Full Report For Exclusive Market Findings:
Which Geographies Are Emerging As Strong Markets For The Monoclonal Antibody Therapeutics Industry?
North America was the largest region in the monoclonal antibody therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the monoclonal antibody therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Monoclonal Antibody Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25839&type=smp
Browse Through More Reports Similar to the Global Monoclonal Antibody Therapeutics Market 2025, By The Business Research Company
Monoclonal Antibodies Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report
Next Generation Antibody Therapeutics Global Market Report 2025
Polyclonal Antibodies Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model